ZOONO GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.055 AUD | -9.84% |
|
-8.33% | +25.00% |
| 23/04 | Zoono Group's Exclusive Agent OSY Signs First Major UK Client; Shares Up 18% | MT |
| 26/03 | Evolution Capital, OSY Group to Underwrite Zoono Group's AU$2.9 Million Rights Issue | MT |
| Sales 2022 | 9.02M 5.35M 8.18M 446M | Sales 2023 | 3.34M 1.98M 3.03M 165M | Capitalization | 7.83M 4.65M 7.11M 387M |
|---|---|---|---|---|---|
| Net income 2022 | -11M -6.53M -9.99M -544M | Net income 2023 | - 0 0 0 | EV / Sales 2022 | 2.27 x |
| Net cash position 2022 | 2.55M 1.51M 2.31M 126M | Net Debt 2023 | 119K 70.33K 108K 5.86M | EV / Sales 2023 | 2.38 x |
| P/E ratio 2022 |
-2.01
x | P/E ratio 2023 |
-19.6
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 33.27% |
More Fundamentals
* Assessed data
More news
| 1 day | -9.84% | ||
| 1 week | -8.33% | ||
| Current month | -54.17% | ||
| 1 month | -56.00% | ||
| 3 months | +10.00% | ||
| 6 months | +27.91% | ||
| Current year | +25.00% |
1 week
0.05
0.08
1 month
0.050.12
Current year
0.030.13
1 year
0.030.13
3 years
0.030.96
5 years
0.033.29
10 years
0.033.29
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Hyslop
CEO | Chief Executive Officer | - | - |
Paul Ravlich
DFI | Director of Finance/CFO | - | 01/17/01 |
Lew MacKinnon
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Clarke
BRD | Director/Board Member | 69 | 26/17/26 |
Elissa Hansen
BRD | Director/Board Member | 51 | 09/15/09 |
Paul Hyslop
CEO | Chief Executive Officer | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.055 | -9.84% | 69,414 |
| 24/24/24 | 0.061 | +1.67% | 381,425 |
| 23/24/23 | 0.06 | +17.65% | 72,351 |
| 22/24/22 | 0.051 | -15.00% | 55,450 |
| 19/24/19 | 0.06 | -1.64% | 83,167 |
Delayed Quote Australian S.E., April 26, 2024 at 10:54 am IST
More quotes
Zoono Group Limited is an Australia-based global biotech company that develops, manufactures and distributes a suite of antimicrobial solutions in multiple countries. The Company produces sprays, wipes and foams suited for skin care, surface sanitizers and mold remediation treatments. Its products are based on the ZOONO molecule, an antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mold. The Company markets its products in various countries, including Australasia, Asia, United States, India, United Kingdom and Europe. Its subsidiaries include Zoono Group Limited (NZ), Zoono Limited, Zoono Holdings Limited (UK), Zoono EU Limited, Zoono (Shanghai) Biotech Co. Limited, Zoono Holdings USA LLC and Zoono South Africa (Pty) Ltd.
Sector
Personal Products
Calendar
22/08/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +25.00% | 7.66M | |
| +8.76% | 129B | |
| +14.18% | 74.67B | |
| -16.59% | 62.59B | |
| +0.82% | 52.86B | |
| -12.40% | 36.11B | |
| +3.54% | 33.57B | |
| +7.92% | 17.29B | |
| +6.30% | 14.75B | |
| -8.65% | 10.82B |
- Stock Market
- Equities
- ZNO Stock
